Original research: Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome
Long-term complications after COVID-19 are common, but the potential cause for persistent symptoms after viral clearance remains unclear.To investigate whether gut microbiome composition is linked to post-acute COVID-19 syndrome (PACS), defined as at ...
Original research Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome - PMC
Long-term complications after COVID-19 are common, but the potential cause for persistent symptoms after viral clearance remains unclear.To investigate whether gut microbiome composition is linked to post-acute COVID-19 syndrome (PACS), defined as at ...
Targeting the monocytic endothelial platelet axis with maraviroc and pravastatin as a therapeutic option to treat long covid post acute sequelae of covid
Vitamin C—An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19
There are limited proven therapies for COVID-19. Vitamin C’s antioxidant, anti-inflammatory and immunomodulating effects make it a potential therapeutic candidate, both for the prevention and amelioration of COVID-19 infection, and as an adjunctive therapy in the critical care of COVID-19. This literature review focuses on vitamin C deficiency in respiratory infections, including COVID-19, and the mechanisms of action in infectious disease, including support of the stress response, its role in preventing and treating colds and pneumonia, and its role in treating sepsis and COVID-19. The evidence to date indicates that oral vitamin C (2–8 g/day) may reduce the incidence and duration of respiratory infections and intravenous vitamin C (6–24 g/day) has been shown to reduce mortality, intensive care unit (ICU) and hospital stays, and time on mechanical ventilation for severe respiratory infections. Further trials are urgently warranted. Given the favourable safety profile and low cost of vitamin C, and the frequency of vitamin C deficiency in respiratory infections, it may be worthwhile testing patients’ vitamin C status and treating them accordingly with intravenous administration within ICUs and oral administration in hospitalised persons with COVID-19.
Long-term persistence of the SARS-CoV-2 spike protein: evidence and implications
This paper discusses the recent study by Bansal et al. on the detection of spike protein in persons vaccinated with the Pfizer mRNA vaccine. The most significant finding is that spike protein is found on exosomes, that is, cell-derived vesicles, for at least four months after the second injection. This surprisingly long persistence raises the prospect of sustained inflammation within and damage to organs which
Dr. Carlos del Rio joins us today to discuss these long-term health consequences of COVID-19 in terms of frequency, mechanisms, and possible therapeutics.
Spike Proteins In Immune Cells - Dr. Bruce Patterson Discusses COVID Long Haul
Spike Proteins In Immune Cells - Dr. Bruce Patterson Discusses COVID Long Haul
Dr. Bruce Patterson’s team has discovered that the S1 pieces of the spike proteins persist in the monocytes resulting in immune dysregulation and long-haul syndrome. Let’s discuss these findings with him.
Dr. Patterson’s site: https://covidlonghaulers.com/
Disclosure:
Dr. Mobeen Syed, or DrBeen have no commercial interest with Dr. Bruce Patterson’s organization.
Want to support this work to get a balanced take on the medical sciences?
Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
Looking to support my educational work? Donate here: https://paypal.me/mobeensyed?locale.x=en_US
Join us on Discord: https://discord.gg/bkmg3rk3sQ
Claim your #koolbeen title here: https://www.drbeen.com/koolbeen-title-registry/
#drbeen #koolbeens #COVID
Predicting & Preventing Long-Haul Covid - with Dr. Heath & Dr. Su The Empowering Neurologist EP146 - YouTube
As it relates to COVID-19, there seems to be an incredible amount of interest in the death rate which happens to be exceedingly, exceedingly low. Why I find this challenging is because there is another problem associated with this infection that isn't getting the type of attention that it deserves. This goes by the common name, long-haul Covid. This simply means that after "recovering" from the initial infection, a fairly significant percentage of individuals continue to experience symptoms that at times may be debilitating.
Research just published has demonstrated an ability to actually predict who is at the greatest risk for developing long-term symptoms after COVID-19 infection. We will be interviewing today Dr. James Heath and Dr. Yapeng Su from the Institute for Systems Biology at the University of Washington. They have identified four characteristics that are clearly and strongly associated with persistent symptoms of Covid-19 and as such, this is important information for all of us. They include:
The presence of particular autoantibodies
A high viral (RNA) load
Type 2 diabetes
Reactivation of the Epstein-Barr virus, which sits latent in the blood of most people following a childhood infection
I’ll tell you more about these dedicated researchers in the intro to the video.
====
TIMESTAMPS:
0:00 Intro
3:40 Important Study on Longterm Effects
7:11 Predicting Severity of Disease
15:00 4 Ways to Predict
21:30 Chronic EBV
26:00 Preventing Long-Haul Covid
39:08 Conclusion
====
James R. Heath, PhD
President and Professor, Institute for Systems Biology
Professor of Bioengineering, Univ of Washington
James Heath serves as the President of the Institute for Systems Biology in Seattle WA. Until early 2018 he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech. For 15 years he directed the National Cancer Institute funded NSB Cancer Center program.
Dr. Heath received a BSc in 1984 from Baylor University and a PhD in chemistry in 1988 from Rice University, where he was the principal student involved in the Nobel Prize–winning discovery of C60 and the fullerenes. He was a Miller Fellow at UC Berkeley from 1988 to 1991 and served on the technical staff at IBM Watson Labs from 1991 to 1993. In 1994 he joined the faculty at UCLA. He founded the California NanoSystems Institute in 2000 and served as its director until moving to Caltech.
Dr. Heath’s lab works on fundamental problems at the interface of the chemical, physical, biological, and biomedical sciences, with focus areas of molecular biotechnologies and oncology. Dr. Heath has published around 400 refereed scientific publications with an h-index of 122.
He has received numerous awards, including a Public Service Commendation from California Governor Grey Davis, the Director’s Service Award from the NCI, the Sackler Prize, Irving Weinstein Award from the AACR, and he was named by Forbes in 2011 as one of the 7 most powerful innovators in the world.. He has founded several companies, including Integrated Diagnostics (sold to Biodesix in 2018), Indi Molecular, PACT Pharma, Sofie Biosciences, ISB BioAnalytica, and Isoplexis (now a public company).
_______
Dr. Yapeng Su received his Ph.D. degree at Caltech, co-advised by Prof. James R. Heath and Prof. David Baltimore. Yapeng’s Ph.D. research resided at the intersection of physical science, biotechnology, and systems biology with a particular focus on cancer. His research utilized systems biology approaches and various single-cell technologies to tackle one of the biggest problems in cancer: drug resistance. His Ph.D. thesis was awarded the highest honor of the Division of Chemistry and Chemical Engineering at Caltech.
After obtaining his Ph.D., Yapeng conducted a brief postdoc research scientist in Prof. Leroy Hood's lab at the Institute for Systems Biology. In close collaboration with a group of world-leading immunologists (Prof. Mark M. Davis, Prof. Phil Greenberg, Prof. Raphael Gottardo, Prof. James R Heath, Prof. Jeff Bluestone, Prof. Lewis Lanier, Prof. Alan Aderem), Yapeng’s research in the Hood lab utilizes data science, multi-omic bulk, and single-cell analysis to investigate the systems immunology of COVID-19. Currently, Yapeng is a Mahan Fellow at the Fred Hutch Cancer Research Center. His research utilized systems-level big data and machine learning to provide rationales on how to better engineer live immune cells as an effective therapy for treating cancer.
___________________________
Instagram: https://www.instagram.com/davidperlmutter/
Website: https://www.drperlmutter.com/
Subscribe to our channel:
https://www.youtube.com/channel/UCDRl_UAXxbHyOOjklnA0dxQ/?sub_confirmation=1
The Link Between Human Retroviruses and Chronic Disease- Interview with Judy Mikovits
Natural health expert and Mercola.com founder Dr. Joseph Mercola interviews Judy Mikovits, a virologist, researcher and founding research director of the Whittemore Peterson Institute, on how retroviruses like XMRV may play a causal role in chronic …
Pathologist on Ryan Cole on the mystery blood clots
He thinks they are due to the vaccine. He couldn't think of any other cause. He only started hearing lots of reports of this in Jan 2022. So it couldn't be caused by COVID. So if it wasn't the vaccine
📲 Get The Fastest No-Log VPN Today 50% OFF: 📲 LINK: https://virtualshield.com/deals/active/sgtreport Start Today For FREE for 30 days ^^ Click Above Hope and Tivon from Fix the World Project Morocco are back with more exhaustive and shocking resear…
Related Posts:Mariazee Hope & Tivon 5G, Nanotech and CovidGraphene Oxide, 5G and Covid Presentation and Notes on SGT…5G and Nanotech in the Covid JabsEMF PROTECTION AFFILIATE PROGRAM (video)5G and Nanotech in the Covid Jabs on Crazz Files
Embalmer Richard Hirschman reveals novel clotting in 65% of cases
Richard Hirschman has been an embalmer for over 20 years. In 2021, he started noticing very odd blood clots that he had never seen before. In Jan 2022, 65% of his cases exhibited these clots. The only